ValidationInstitute

2026 - 2027 Validation Report

Review for: TempraMed

Validation Achieved: Savings & Metrics

Valid through: January 2027

Company Profile

TempraMed

Category:	**Diabetes Management**
Website:	https://tempramed.com/
Public or Private:	Public
Year Established:	2014
CEO:	Ron Nagar
Company contact:	ron@tempramed.com

Description Provided by the Company:

TempraMed Technologies Ltd. is a global leader in innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, **TempraMed** develops patented, FDA-registered, space-grade thermal insulation devices that work 24/7 without batteries or external power. With a proven product line including VIVI Cap and VIVI Epi, and a smart technology platform on the horizon, **TempraMed** enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime. **TempraMed** is advancing the future of medication protection and adherence.

Claim Assertion for Validation

By providing a temperature shield to medications in-use which degrade when exposed to temperatures exceeding “room temperatures” or below freezing, for patients that spend time outdoors with their medication, the VIVI CAP device can provide significant savings. Some of the savings is almost in real time due to reduced medication wastage. Longer-term savings include, among other things, reduced patient anxiety. Anxiety over meds effectiveness and their disease management, which often results in doctor visits[1].

Method / Calculation / Examples

Validation included checking the consistency of the arithmetic and the reasonability of the assumptions, and ensuring that the links provided supported those assumptions.



Findings & Validation

Many drugs require refrigeration, and the potency/efficacy is diminished or negated if not properly refrigerated. In a worst-case scenario, significant harms can result from improperly stored drugs. Hence drugs whose chain-of-custody includes ongoing temperature monitoring have a substantial advantage. Notification if refrigeration has not been consistent means the drugs must be thrown out, to avoid the aforementioned risks or harms.

In addition to preventing harms, research has shown that confidence in refrigeration significantly reduces clinical interactions driven by user anxiety.

While we don't validate the actual technology of the TempraMed solution, we do validate the economics and savings calculations. The model accurately captures the correct arithmetic and is pre-populated with reasonable assumptions, which in turn may be changed. It also offers among the most user-friendly interfaces in the Validation Institute community of Metrics-validated organizations.

Limitations

Because this is a model with an underlying Metrics Validation to support the Savings Validation, there are no significant knowable Limitations. One can simply change the assumptions to avoid any perceived limitations.

Works Cited

1. Iturralde E. et al., "Anxiety disorders increase hospital visits, costs in type 2 diabetes", Diabetes Care (2019). 42(9):1637-1644
2. Economic Costs of Diabetes in the U.S. in 2022, Diabetes Care Journal, American Diabetes Association (2023). DOI: 10.2337/dc22-0292
3. National Diabetes Statistics Report, Centers for Disease Control and Prevention, CDC.gov (2024). Retrieved from https://www.cdc.gov/diabetes/data/statisticsreport/
4. Iturralde E. et al., "Anxiety disorders increase hospital visits, costs in type 2 diabetes", Diabetes Care (2019). 42(9):1637-1644
5. GoodRx, Cost-effective Drug Sourcing, Insulin and GLP-1 Price Analysis (2024). GoodRx.com/research
6. JAMA Network, "Price Analysis of GLP-1 Receptor Agonists and Biologics", JAMA Open Network (2024). 5(2):e220164
7. Manufacturer labels (FDA.gov): Storage and handling guidelines for Ozempic, Humira, EpiPen, and other temperature-sensitive medications
8. American Diabetes Association, "Standards of Medical Care in Diabetes" (2024), Diabetes Care, 47(Supplement 1)
9. Gilmer T.P. et al., "The cost to health plans of poor glycemic control", Diabetes Care (2021), 44(8):1771–1779
10. Pfutzner et al. "A Reusable Cap for Disposable Insulin Pens Protects Insulin against Temperature-Induced Degradation" Diabetes 2018;67(Supplement_1):2281-PUB
11. Pfutzner et al. "Technology-derived storage solutions for stabilizing insulin in extreme weather conditions I: the ViViCap-1 device" Expert Opin Drug Deliv 2017 Jun;14(6):709-714.

Validation and Credibility Guarantee

TempraMed has achieved validation for Savings and Metrics. Validation Institute is providing a $100,000 guarantee as an ERISA/Credibility Guarantee that the methodology used *exceeds* the diabetes/medication therapy management industry standard for savings calculations. To learn more, visit: https://validationinstitute.com/credibility-guarantee/.

Savings
Can reduce health care spending per case/participant or for the plan/purchaser overall.

Metrics
Credible sources and valid assumptions create a reasonable estimate of a program's impact.

VALIDATION INSTITUTE
500 Westover Drive #23729,
Sanford, North Carolina 27330

Validation Expiration: January 2027

CERTIFICATE OF VALIDATION

Applicant:	**TempraMed** 19481 SE 14th St, Sammamish, Washington 98075, US
Product:	**VIVI CAP**
Claim:	Payors that provide coverage to VIVI CAP device can experience cost savings and have fast return on investment to payors.
Validation Achieved:	**Validated for Savings and Metrics**
Validation Award Date:	**January 2026**

Al Lewis
Founder & Validator-In-Chief
Validation Institute

About Validation Institute

Validation Institute is a professional community that advocates for organizations and approaches that deliver better health value - stronger health outcomes at lower cost. We connect, train, and certify health care purchasers, and we validate and connect providers delivering superior results. Founded in 2014, the mission of the organization has consistently been to help provide transparency to buyers of health care.

Validation Review Process

Validation Institute has a team of epidemiologists and statisticians who review each program. The team focuses on three components:

- Evidence from published literature that a similar intervention had similar results.
- The reliability and credibility of the data sources.
- The rigor of the approach to calculating results.

To achieve validation, the program has to satisfy each of these components. VI's team then summarizes the review into a report which is publicly available. Details of VI's review are available with the program's permission.